When is osteonecrosis not osteonecrosis? adjudication of reported serious adverse joint events in the tanezumab clinical development program

Conclusions: Despite initial reports, tanezumab treatment was not associated with an increase in ON, but was associated with an increase in RPOA. Higher doses of tanezumab, tanezumab administered with NSAIDs, and preexisting subchondral insufficiency fractures were risk factors for RPOA in this cohort. This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatism - November 10, 2015 Category: Rheumatology Authors: Marc C. Hochberg, Leslie A. Tive, Steven B. Abramson, Eric Vignon, Kenneth M. Verburg, Christine R. West, Mike D. Smith, David S. Hungerford Tags: Full Length Source Type: research